Sogroya Injection, Solution
Product Images NDC 0169-2035

161 FDA label images from Novo Nordisk · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 161 technical images submitted to the FDA as part of the official labeling for Sogroya (NDC 0169-2035). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Molecular-structure (Image 02)

Molecular-structure (Image 02)
Chemical structure diagram showing the peptide sequence and molecular structure of somapacitan-beco, the active ingredient in SOGROYA injection solution by Novo Nordisk.*
FDA Label Image

5mg-pen-body (5mg Pen Body.jpg)

5mg-pen-body (5mg Pen Body.jpg)
An illustration of the SOGROYA Pen, a subcutaneous injection device for somapacitan-beco. The diagram labels key components including the pen window, pen scale, dose counter, dose pointer, dose selector, and dose button, highlighting its user interface for dose administration.*
FDA Label Image

5mg-pen-cap (5mg Pen Cap 01.jpg)

5mg-pen-cap (5mg Pen Cap 01.jpg)
Illustration showing the pen cap of a subcutaneous injection device, labeled as Pen cap, likely part of the SOGROYA somapacitan-beco injection system for subcutaneous use.*
FDA Label Image

5mg-needle-parts (5mg Needle Parts 01.jpg)

5mg-needle-parts (5mg Needle Parts 01.jpg)
An instructional diagram showing a subcutaneous injection needle assembly with labeled components: outer needle cap, inner needle cap, needle, and paper tab. The illustration visually distinguishes each part of the needle setup, aiding in proper handling and identification.*
FDA Label Image

Supplies (Supplies 01.jpg)

Supplies (Supplies 01.jpg)
SOGROYA injection solution for subcutaneous use, shown with an empty bottle outline and a pre-filled pen injector in green and dark blue. Also visible are a transparent adhesive patch, white square pad, and small white nozzle or applicator component, associated with the injection administration. Labeler: Novo Nordisk.*
FDA Label Image

Triangle-bullet (Triangle Bullet)

FDA Label Image

Letteri-bullet (Letteri Bullet.jpg)

Letteri-bullet (Letteri Bullet.jpg)
SOGROYA 10 mg/mL injection solution for subcutaneous use in a vial. The label includes the proprietary name, strength, dosage form, route of administration, and the labeler Novo Nordisk. The vial has a green cap and a white label with text.*
FDA Label Image

Figure-a (Figure A 02.jpg)

Figure-a (Figure A 02.jpg)
An instructional illustration showing a close-up of a hand holding a subcutaneous injection device, highlighting the needle area for use with SOGROYA (somapacitan-beco) injection solution by Novo Nordisk.*
FDA Label Image

Figure-b (Figure B 02.jpg)

Figure-b (Figure B 02.jpg)
Illustration showing a hand holding a SOGROYA injection pen, twisting the pen cap counterclockwise as indicated by a blue arrow. The image appears instructional, likely demonstrating part of the injection preparation or administration process for somapacitan-beco subcutaneous injection.*
FDA Label Image

Triangle-bullet (Triangle Bullet 01)

FDA Label Image

Triangle-bullet (Triangle Bullet 02)

FDA Label Image

Figure-c (Figure C 02.jpg)

Figure-c (Figure C 02.jpg)
An instructional diagram showing a hand removing a cap from the end of an injection pen or syringe. The illustration indicates the cap being pulled off with a hand, accompanied by arrows demonstrating the direction of the removal.*
FDA Label Image

Letteri-bullet (Letteri Bullet 01.jpg)

Letteri-bullet (Letteri Bullet 01.jpg)
SOGROYA injection solution carton displaying three available strengths: 10 mg/mL, 3.3 mg/mL, and 6.7 mg/mL. The product contains the active ingredient somapacitan-beco and is intended for subcutaneous human prescription use. The labeler is Novo Nordisk. The packaging features a white background with black text and blue highlight elements.*
FDA Label Image

Figure-d (Figure D 02.jpg)

Figure-d (Figure D 02.jpg)
An instructional illustration showing a hand holding a device and removing a protective cap, with an inset image depicting the disposal of the cap into a container. The diagram appears to be part of a guide for preparing a subcutaneous injection device.*
FDA Label Image

Triangle-bullet (Triangle Bullet 03)

FDA Label Image

Letteri-bullet (Letteri Bullet 02.jpg)

Letteri-bullet (Letteri Bullet 02.jpg)
SOGROYA injection, 10 mg/mL solution in a vial, for subcutaneous use. The carton and vial labels indicate the product name SOGROYA, its active ingredient somapacitan-beco, and the strength of 10 mg/mL. The manufacturer is Novo Nordisk. The package shows one vial inside the carton.*
FDA Label Image

Figure-e (Figure E 03.jpg)

Figure-e (Figure E 03.jpg)
Illustration showing hands holding and adjusting a dose selector on a SOGROYA (somapacitan-beco) injection pen, a subcutaneous solution for injection by Novo Nordisk. The image focuses on setting the dosage amount on the pen device dial.*
FDA Label Image

Figure-f (Figure F 03.jpg)

Figure-f (Figure F 03.jpg)
An illustration showing the dose window on a SOGROYA injection pen, with the dose setting indicating 0.05 mg. The image highlights the dosage scale visible through the pen's dose display window.*
FDA Label Image

Figure-g (Figure G 03.jpg)

Figure-g (Figure G 03.jpg)
An instructional diagram shows a hand holding and lifting a medication pen device vertically. The device is marked with a 3 mg dose indicator. An upward arrow indicates the direction to move the pen. This likely depicts a step in preparing or adjusting the injection dose for SOGROYA (somapacitan-beco) injection.*
FDA Label Image

Letteri-bullet (Letteri Bullet 03.jpg)

Letteri-bullet (Letteri Bullet 03.jpg)
SOGROYA 10 mg/mL injection, solution for subcutaneous use, presented in a 1 mL single-dose cartridge. The label includes dosing information and storage instructions, with the product labeled by Novo Nordisk for human prescription use.*
FDA Label Image

Figure-h (Figure H 03.jpg)

Figure-h (Figure H 03.jpg)
An instructional diagram illustrating the tip of a pen-type injector device with the needle exposed and a small droplet visible at the needle's end, likely demonstrating the preparation or priming of a subcutaneous injection device.*
FDA Label Image

Letteri-bullet (Letteri Bullet 04.jpg)

Letteri-bullet (Letteri Bullet 04.jpg)
SOGROYA injection solution subcutaneous vial packaging showing the product name and strength of 3.3 mg/mL. The label includes the generic name somapacitan-beco and is manufactured by Novo Nordisk. The vial contains 3 mL of solution as indicated on the label.*
FDA Label Image

Figure-i (Figure I 03.jpg)

Figure-i (Figure I 03.jpg)
Illustration showing a person holding a SOGROYA injection device, with a close-up on the dosage dial indicating 0 mg, and arrows demonstrating the rotation of the dosage knob to adjust the dose for subcutaneous administration.*
FDA Label Image

Letteri-bullet (Letteri Bullet 05.jpg)

Letteri-bullet (Letteri Bullet 05.jpg)
SOGROYA 10 mg/mL injection, solution in a vial of 1 mL for subcutaneous use. The label shows the proprietary name SOGROYA prominently, with the active ingredient somapacitan-beco, and the concentration 10 mg/mL. The manufacturer is Novo Nordisk A/S, Denmark. Additional information includes storage conditions and handling instructions visible on the label.*
FDA Label Image

Figure-j (Figure I 04.jpg)

Figure-j (Figure I 04.jpg)
Illustration showing a dosage selector on an injection device with a close-up of the dosage window. The example dosage displayed is 1.575 mg, indicating adjustable dosing in milligrams for subcutaneous injection.*
FDA Label Image

Figure-k (Figure K 03.jpg)

Figure-k (Figure K 03.jpg)
An illustration showing a close-up of a dosage selector on the SOGROYA injection pen, indicating an example dose of 1.5 mg selected. The image highlights how to adjust the dose visible through a small window on the pen.*
FDA Label Image

Letteri-bullet (Letteri Bullet 06.jpg)

Letteri-bullet (Letteri Bullet 06.jpg)
SOGROYA (somapacitan-beco) injection, solution, subcutaneous, shown in a vial. The vial label displays the proprietary name SOGROYA prominently, along with the concentration of 10 mg/mL. The label includes dosage form and route of administration and notes Novo Nordisk as the labeler.*
FDA Label Image

Figure-l (Figure L 03.jpg)

Figure-l (Figure L 03.jpg)
Illustration depicting hands adjusting the dosage setting on a SOGROYA (somapacitan-beco) injection pen. The dose display shows 1.8 mg, with arrows indicating rotation for dose adjustment, relevant for the subcutaneous injection solution by Novo Nordisk.*
FDA Label Image

Figure-m (Figure M 03.jpg)

Figure-m (Figure M 03.jpg)
An illustration showing a simplified human figure highlighting recommended injection sites. The marked areas are on the abdomen and both the front and back of the thighs, indicating typical locations for subcutaneous injections. No specific product details or text are visible in the image.*
FDA Label Image

Figure-n (Figure N 02.jpg)

Figure-n (Figure N 02.jpg)
An instructional diagram showing how to hold and inject a SOGROYA injection pen. The hand grips the pen vertically with the needle pointing downward, indicated by a large downward arrow, demonstrating the correct injection orientation for subcutaneous administration.*
FDA Label Image

Letteri-bullet (Letteri Bullet 07.jpg)

Letteri-bullet (Letteri Bullet 07.jpg)
SOGROYA 3.3 mg/mL injection solution for subcutaneous use in a box and vial. The packaging displays the proprietary name SOGROYA and the active ingredient somapacitan-beco. The labeler is Novo Nordisk. The vial contains 3.3 mg/mL strength and is part of a set that includes other concentrations.*
FDA Label Image

Figure-o (Figure O 03.jpg)

Figure-o (Figure O 03.jpg)
An instructional illustration showing a hand holding a SOGROYA prefilled injection pen vertically above the skin, with a downward arrow indicating injection. A close-up inset displays a dial with a '0' dosage reading on the device, representing dose setting or confirmation before subcutaneous injection.*
FDA Label Image

Figure-p (Figure O 04.jpg)

Figure-p (Figure O 04.jpg)
An instructional illustration showing a hand holding an injection pen for subcutaneous use. The image instructs the user to count slowly from 1 to 6 during injection administration, visually emphasizing the numbers 1 through 6.*
FDA Label Image

Letteri-bullet (Letteri Bullet 08.jpg)

Letteri-bullet (Letteri Bullet 08.jpg)
Box packaging label for SOGROYA injection, solution, showing the product name and strength 3.3 mg/mL. It indicates a subcutaneous route of administration and displays the Novo Nordisk labeler logo and branding. The label is primarily white with purple and gray design elements.*
FDA Label Image

Figure-q (Figure Q 03.jpg)

Figure-q (Figure Q 03.jpg)
An instructional diagram showing a close-up of an injection pen needle with an upward-pointing arrow beside it, likely indicating the direction to remove or attach the needle. The image is a simplified line drawing focusing on the needle attachment area of the device.*
FDA Label Image

Letteri-bullet (Letteri Bullet 09.jpg)

Letteri-bullet (Letteri Bullet 09.jpg)
SOGROYA 10 mg/mL injection solution in a clear glass vial with blue cap and red text on the label. The label features the product name, strength, and some usage instructions, indicating the vial contains subcutaneous injection solution. The manufacturer is Novo Nordisk.*
FDA Label Image

Figure-r (Figure R 03.jpg)

Figure-r (Figure R 03.jpg)
An instructional illustration showing a hand twisting and removing the cap from a small injection device or cartridge, likely demonstrating preparation for subcutaneous injection. The image includes an inset showing the cap being lifted off a container.*
FDA Label Image

Figure-s (Figure S 03.jpg)

Figure-s (Figure S 03.jpg)
Illustration showing two hands handling a device component with an arrow indicating the direction to pull or slide a part of the device. The image likely demonstrates a step in the preparation or assembly process for SOGROYA (somapacitan-beco) injection.*
FDA Label Image

Triangle-bullet (Triangle Bullet 04)

FDA Label Image

Triangle-bullet (Triangle Bullet 05)

FDA Label Image

Figure-t (Figure T 03.jpg)

Figure-t (Figure T 03.jpg)
An instructional illustration showing the pen scale on an injection pen device, indicating approximate medication remaining, labeled with an example marking for approximately 1 mg left. The visible scale markings are numbered 1 through 3.*
FDA Label Image

Figure-u (Figure U 03.jpg)

Figure-u (Figure U 03.jpg)
An instructional illustration showing how to read the remaining dose amount on the SOGROYA injection pen, indicating 1.7 mg left. The image depicts a hand holding the pen and a close-up of the digital dose display.*
FDA Label Image

Triangle-bullet (Triangle Bullet 06)

FDA Label Image

10mg-pen-body (10mg Pen Body.jpg)

10mg-pen-body (10mg Pen Body.jpg)
Illustration of the SOGROYA Pen, a subcutaneous injection device for somapacitan-beco. The pen is labeled with the product name and strength 10 mg/1.5 mL (6.7 mg/mL). Key components labeled include the pen window, pen scale, dose counter, dose pointer, dose selector, and dose button, showing how the pen is used for dose administration.*
FDA Label Image

10mg-pen-cap (10mg Pen Cap 01.jpg)

10mg-pen-cap (10mg Pen Cap 01.jpg)
Illustration showing a yellow pen cap for the SOGROYA somapacitan-beco injection device. The pen cap is labeled clearly, indicating its part in the injection system.*
FDA Label Image

Pen-needle (Pen Needle 01.jpg)

Pen-needle (Pen Needle 01.jpg)
An instructional diagram showing four components of a needle for subcutaneous injection: outer needle cap, inner needle cap, needle, and paper tab, displayed from left to right with labels for each part.*
FDA Label Image

Supplies (Supplies.jpg)

Supplies (Supplies.jpg)
An instructional illustration showing components associated with the SOGROYA injection, including a vial, a pen injector device, a blister pack with an adhesive patch, a square dressing, and a nozzle or cap. These items represent the typical packaging and application materials for the subcutaneous injection solution somapacitan-beco by Novo Nordisk.*
FDA Label Image

Triangle-bullet (Triangle Bullet 07)

FDA Label Image

Letteri-bullet (Letteri Bullet 10.jpg)

Letteri-bullet (Letteri Bullet 10.jpg)
SOGROYA (somapacitan-beco) injection, solution for subcutaneous use is shown with three vial sizes representing strengths of 3.3 mg/mL, 6.7 mg/mL, and 10 mg/mL. The packaging and vial labels include Novo Nordisk branding and dosage information, clearly indicating the medication as a prescription drug.*
FDA Label Image

Figure-a (Figure A 01.jpg)

Figure-a (Figure A 01.jpg)
An illustration showing a hand holding an injection pen device likely used for administering SOGROYA (somapacitan-beco) subcutaneous injection. The needle end of the pen is shown on the right, with indicators or markings visible on the pen body.*
FDA Label Image

Figure-b (Figure B 01.jpg)

Figure-b (Figure B 01.jpg)
Illustration showing a hand grasping the yellow cap of a pen injector device. An arrow indicates the cap is being twisted or removed, demonstrating a step in using the injection device for SOGROYA (somapacitan-beco).*
FDA Label Image

Triangle-bullet (Triangle Bullet 08)

FDA Label Image

Triangle-bullet (Triangle Bullet 09)

FDA Label Image

Figure-c (Figure C 01.jpg)

Figure-c (Figure C 01.jpg)
An instructional diagram showing a hand gripping and twisting a plastic cap or component of a device, indicated by an arrow pointing right. A smaller inset illustrates the cap being removed or opened by pulling upward. The image likely demonstrates part of the preparation or assembly process for a subcutaneous injection device or vial.*
FDA Label Image

Letteri-bullet (Letteri Bullet 11.jpg)

Letteri-bullet (Letteri Bullet 11.jpg)
SOGROYA 6.7 mg/mL injection, solution for subcutaneous use. The image shows a mostly white cartridge with black and red markings, labeled with the brand name SOGROYA. The label lists concentration as 6.7 mg/mL, displays measurement gradations, and includes the Novo Nordisk logo at the bottom. The cartridge is part of a prefilled injection device.*
FDA Label Image

Figure-d (Figure D 01.jpg)

Figure-d (Figure D 01.jpg)
Instructional illustration showing a hand removing a cap from the needle of a subcutaneous injection pen device. The image includes an arrow indicating the direction to pull the cap off and a smaller inset zooming on the cap removal step.*
FDA Label Image

Important-information_small (Export 00)

Important-information_small (Export 00)
SOGROYA injection solution carton showing three different strengths: 3.3 mg/mL, 6.7 mg/mL, and 10 mg/mL of somapacitan-beco for subcutaneous use. The labels display the proprietary name, dosage form, and Novo Nordisk as the labeler.*
FDA Label Image

Letteri-bullet (Letteri Bullet 12.jpg)

Letteri-bullet (Letteri Bullet 12.jpg)
The carton for SOGROYA injection, solution, showing the 10 mg/mL strength. The label displays the proprietary name SOGROYA and the generic name somapacitan-beco. The dosage form noted is a subcutaneous injection, and the labeler is Novo Nordisk. The package appears to be a single vial or container with clear text on a white background with a purple and blue color scheme.*
FDA Label Image

Figure-e (Figure E 02.jpg)

Figure-e (Figure E 02.jpg)
An instructional illustration showing hands adjusting the dosage dial on a SOGROYA (somapacitan-beco) injection device. The image highlights turning the dose selector to set the desired milligram amount for subcutaneous injection.*
FDA Label Image

Figure-f (Figure F 02.jpg)

Figure-f (Figure F 02.jpg)
An illustration of a SOGROYA (somapacitan-beco) injection pen dose window showing a dose setting of 0.1 mg. The pen features a numeric display with an arrow pointing to the selected dose, indicating adjustable dosing for subcutaneous injection.*
FDA Label Image

Figure-g (Figure G 02.jpg)

Figure-g (Figure G 02.jpg)
Instructional illustration for SOGROYA injection showing a hand holding the injection device with an upward arrow, indicating removal or detachment of a component. No text beyond the device label is visible.*
FDA Label Image

Letteri-bullet (Letteri Bullet 13.jpg)

Letteri-bullet (Letteri Bullet 13.jpg)
SOGROYA (somapacitan-beco) injection, solution for subcutaneous use, available in strengths of 10 mg/mL, 3.3 mg/mL, and 6.7 mg/mL. The carton packaging is labeled with the Novo Nordisk logo and indicates it is a human prescription drug. The box includes product name, strength, and indication of injectable form.*
FDA Label Image

Figure-h (Figure H 02.jpg)

Figure-h (Figure H 02.jpg)
An illustration showing a close-up of the top part of a medical device or injection pen, featuring a white dial or cap with a small flag-like pointer at the top and a yellow base. This image likely relates to the usage or assembly of the SOGROYA injection product.*
FDA Label Image

Letteri-bullet (Letteri Bullet 14.jpg)

Letteri-bullet (Letteri Bullet 14.jpg)
SOGROYA injection, solution for subcutaneous use, available in 10 mg/mL strength. The packaging is a primarily white and purple carton containing 1 prefilled, disposable pen with 3 mL solution for injection. The labeler is Novo Nordisk. The product shows the proprietary name 'SOGROYA' and active ingredient 'somapacitan-beco' on the front of the carton.*
FDA Label Image

Figure-i (Figure I 02.jpg)

Figure-i (Figure I 02.jpg)
An instructional diagram showing how to adjust the dose on a SOGROYA somapacitan-beco injection pen by turning the dose selector dial. The pen is held in both hands with the thumb and index finger rotating the dosage window to select the desired milligram amount for subcutaneous injection.*
FDA Label Image

Letteri-bullet (Letteri Bullet 15.jpg)

Letteri-bullet (Letteri Bullet 15.jpg)
The image shows the vial of SOGROYA 10 mg/mL injection, solution for subcutaneous use. The vial label displays the product name, concentration, dosage form, and route of administration. The labeler is Novo Nordisk. The vial includes a bar code and lot or batch number information as typically found on prescription drug packaging.*
FDA Label Image

Figure-j (Figure J 02.jpg)

Figure-j (Figure J 02.jpg)
An instructional diagram showing a dosing selector on a SOGROYA (somapacitan-beco) injection device. The window displays a dose setting example of 2.95 mg, illustrating how the dose can be adjusted on the subcutaneous injection pen.*
FDA Label Image

Figure-k (Figure K 02.jpg)

Figure-k (Figure K 02.jpg)
Close-up illustration showing a dose selector on a blue and gray injection device for SOGROYA (somapacitan-beco). The dose window highlights a selected dose of 1.5 mg, with mg units visible on the right side. The image demonstrates how to select a specific dose on the injection pen.*
FDA Label Image

Letteri-bullet (Letteri Bullet 16.jpg)

Letteri-bullet (Letteri Bullet 16.jpg)
SOGROYA injection, solution, 10 mg/mL in a 3 mL clear glass vial with a blue and white flip-off cap, labeled for subcutaneous use. The vial label includes the proprietary name SOGROYA, the nonproprietary name somapacitan-beco, and branding from Novo Nordisk.*
FDA Label Image

Figure-l (Figure L 02.jpg)

Figure-l (Figure L 02.jpg)
An instructional illustration showing hands adjusting the dose on a SOGROYA (somapacitan-beco) injection device. The dose window displays a partial dose setting with an arrow indicating rotation to change the dosage amount for subcutaneous injection.*
FDA Label Image

Figure-m (Figure M 02.jpg)

Figure-m (Figure M 02.jpg)
An anatomical illustration indicating subcutaneous injection sites on the human body. Highlighted areas include the abdomen and upper thighs, guiding where the SOGROYA (somapacitan-beco) injection solution can be administered subcutaneously.*
FDA Label Image

Figure-n (Figure N 03.jpg)

Figure-n (Figure N 03.jpg)
An instructional illustration showing a hand holding a SOGROYA injection device vertically with the needle end pointing downward towards the injection site, accompanied by a downward arrow indicating the correct direction for subcutaneous administration.*
FDA Label Image

Letteri-bullet (Letteri Bullet 17.jpg)

Letteri-bullet (Letteri Bullet 17.jpg)
SOGROYA 10 mg/mL injection, solution, subcutaneous use in a vial. The label includes the proprietary name SOGROYA and the generic name somapacitan-beco. The manufacturer is Novo Nordisk. The vial appears to be sealed with a light-blue cap and glass container showing the solution inside.*
FDA Label Image

Figure-o (Figure O 02.jpg)

Figure-o (Figure O 02.jpg)
Instructional illustration depicting the correct technique to hold and administer a SOGROYA (somapacitan-beco) injection pen subcutaneously. The image shows a hand gripping the injection pen with a downward arrow indicating the direction for injection into the skin.*
FDA Label Image

Figure-p (Figure P 02.jpg)

Figure-p (Figure P 02.jpg)
An instructional illustration showing a hand holding an injection device against a forearm, with a prompt to count slowly from 1 to 6. This demonstrates the proper administration timing for a subcutaneous injection, presumably for the SOGROYA injection solution.*
FDA Label Image

Letteri-bullet (Letteri Bullet 18.jpg)

Letteri-bullet (Letteri Bullet 18.jpg)
SOGROYA 10 mg/mL injection solution vial for subcutaneous use. The label displays the product name SOGROYA and active ingredient somapacitan-beco. Labeler information is Novo Nordisk. The vial is amber-colored with a white cap and a detailed printed label including strength and usage instructions.*
FDA Label Image

Figure-q (Figure Q 02.jpg)

Figure-q (Figure Q 02.jpg)
An instructional illustration showing a close-up of the tip of a pen injector device with a blue upward-pointing arrow beneath it, likely indicating the direction to pull or remove a cap or cover from the injection needle.*
FDA Label Image

Letteri-bullet (Letteri Bullet 19.jpg)

Letteri-bullet (Letteri Bullet 19.jpg)
SOGROYA 10 mg/mL injection, solution for subcutaneous use in a vial. The label shows the brand name, strength (10 mg/mL), and indicates it is a solution for injection. The product is labeled by Novo Nordisk. The vial has a purple cap and includes bilingual text in English and French.*
FDA Label Image

Figure-r (Figure R 02.jpg)

Figure-r (Figure R 02.jpg)
Instructional illustration showing a hand twisting the cap off a small vial or cartridge to open it, with an inset indicating the removal of the cap for access. This image is likely part of a usage or preparation guide for the SOGROYA (somapacitan-beco) injection solution.*
FDA Label Image

Figure-s (Figure S 02.jpg)

Figure-s (Figure S 02.jpg)
An instructional illustration showing a pair of hands holding a yellow injection pen device for SOGROYA (somapacitan-beco) injection, solution. The left hand is pulling off a protective cap or cover from the pen, indicated by a leftward pointing arrow.*
FDA Label Image

Triangle-bullet (Triangle Bullet 10)

FDA Label Image

Triangle-bullet (Triangle Bullet 11)

FDA Label Image

Figure-t (Figure T 02.jpg)

Figure-t (Figure T 02.jpg)
Illustration of a yellow injection pen dose scale for SOGROYA (somapacitan-beco) showing dose markings at 2, 4, and 6 mg with an example dose window indicating approximately 2 mg left in the pen.*
FDA Label Image

Figure-u (Figure U 02.jpg)

Figure-u (Figure U 02.jpg)
An instructional illustration showing a person adjusting the dosage dial on a SOGROYA (somapacitan-beco) injection pen, indicating the amount of medication left in milligrams, with an example display of 2.8 mg remaining.*
FDA Label Image

Triangle-bullet (Triangle Bullet 12)

FDA Label Image

15mg-pen-body (15mg Pen Body.jpg)

15mg-pen-body (15mg Pen Body.jpg)
Illustration of a SOGROYA pen injector for somapacitan-beco injection, showing labeled parts including the pen window, pen scale, dose counter, dose pointer, dose selector, and dose button. The pen label indicates the strength as 10 mg/mL (15 mg/1.5 mL).*
FDA Label Image

15mg-pen-cap (15mg Pen Cap 01.jpg)

15mg-pen-cap (15mg Pen Cap 01.jpg)
An illustration of a pen cap, labeled to identify it as the 'Pen cap.' The image shows a close-up view of a cylindrical, pink pen cap used for a subcutaneous injection device.*
FDA Label Image

15mg-needle-parts (15mg Needle Parts 01.jpg)

15mg-needle-parts (15mg Needle Parts 01.jpg)
An instructional illustration showing components of a needle assembly including an outer needle cap, inner needle cap, needle, and a paper tab, labeled as an example. The parts are displayed in a linear sequence from left to right for clarity.*
FDA Label Image

15mg-supplies (15mg Supplies.jpg)

15mg-supplies (15mg Supplies.jpg)
Illustration showing components of the SOGROYA injection solution package, including a vial, a prefilled injection pen, an adhesive patch, a square gauze pad, and a small cap or nozzle, representing parts used for subcutaneous administration by Novo Nordisk.*
FDA Label Image

Triangle-bullet (Triangle Bullet 13)

FDA Label Image

Letteri-bullet (Letteri Bullet 20.jpg)

Letteri-bullet (Letteri Bullet 20.jpg)
SOGROYA injection solution cartons in multiple strengths: 10 mg/mL, 6.7 mg/mL, and 3.3 mg/mL. The product contains somapacitan-beco and is indicated for subcutaneous administration. The packaging shows Novo Nordisk as the labeler.*
FDA Label Image

Figure-a (Figure A.jpg)

Figure-a (Figure A.jpg)
An instructional illustration showing a hand holding a red and gray subcutaneous injection pen device, likely related to administration instructions for SOGROYA (somapacitan-beco) injection.*
FDA Label Image

Figure-b (Figure B.jpg)

Figure-b (Figure B.jpg)
Illustration showing a hand gripping the cap of an injector pen, demonstrating how to twist and remove the pen cap as part of the injection preparation process for a subcutaneous injection device.*
FDA Label Image

Triangle-bullet (Triangle Bullet 14)

FDA Label Image

Triangle-bullet (Triangle Bullet 15)

FDA Label Image

Figure-c (Figure C.jpg)

Figure-c (Figure C.jpg)
An instructional illustration showing a hand gripping a bottle and attaching a device or applicator by pushing it downward onto the bottle opening. Arrows indicate the motion to attach the component securely.*
FDA Label Image

Letteri-bullet (Letteri Bullet 21.jpg)

Letteri-bullet (Letteri Bullet 21.jpg)
SOGROYA injection, solution for subcutaneous use, showing multiple vials labeled with strengths 10 mg/mL, 6.7 mg/mL, and 3.3 mg/mL of the active ingredient somapacitan-beco. The labeler is Novo Nordisk. The packaging contains several glass vials with color-coded caps corresponding to each strength.*
FDA Label Image

Figure-d (Figure D.jpg)

Figure-d (Figure D.jpg)
An instructional diagram showing a hand removing a cap from a pen injector device, with an inset illustrating the cap being placed on a surface. The image appears to be part of preparation steps for using the injection device.*
FDA Label Image

Triangle-bullet (Triangle Bullet 16)

FDA Label Image

Letteri-bullet (Image 03)

FDA Label Image

Figure-e (Figure E 01.jpg)

Figure-e (Figure E 01.jpg)
An instructional illustration showing hands adjusting the dose setting on a SOGROYA (somapacitan-beco) injection pen. The image highlights a rotating dial with a visible dose display window, indicating a subcutaneous injection dose adjustment step for the medication.*
FDA Label Image

Figure-f (Figure F 01.jpg)

Figure-f (Figure F 01.jpg)
Illustration showing a close-up of the dose selector window on a SOGROYA (somapacitan-beco) injection pen. The window displays numerical values for dose measurement, indicating precise dosing adjustments in milligrams.*
FDA Label Image

Figure-g (Figure G 01.jpg)

Figure-g (Figure G 01.jpg)
An instructional illustration showing a hand holding a SOGROYA injection pen with a visible 6 mg dose indicator. The image depicts the step of pushing or sliding the pen upward, indicated by a large upward arrow, likely demonstrating part of the medication administration process.*
FDA Label Image

Letteri-bullet (Letteri Bullet 22.jpg)

Letteri-bullet (Letteri Bullet 22.jpg)
SOGROYA 10 mg/mL injection solution cartridge, a human prescription drug for subcutaneous use. The label displays the proprietary name SOGROYA prominently along with the strength of 10 mg/mL. It is labeled as somapacitan-beco, produced by Novo Nordisk, suitable for use with a specific injection device as indicated by the cartridge form shown.*
FDA Label Image

Figure-h (Figure H 01.jpg)

Figure-h (Figure H 01.jpg)
An illustration showing the top portion of a device with a white cap and a small, flexible tab or flag extending from the center. The device has a red body partially visible below the cap, likely representing a component of the SOGROYA injection delivery system.*
FDA Label Image

Letteri-bullet (Letteri Bullet 23.jpg)

Letteri-bullet (Letteri Bullet 23.jpg)
SOGROYA injection, solution, subcutaneous, with a strength of 3.3 mg/mL. The label shows the proprietary name SOGROYA and the generic name somapacitan-beco. Packaging includes dosage information and the labeler Novo Nordisk is indicated on the label.*
FDA Label Image

Figure-i (Figure I 01.jpg)

Figure-i (Figure I 01.jpg)
An instructional illustration showing two hands adjusting the dose selector on a SOGROYA (somapacitan-beco) injection pen. The dose window displays a numeric dose in milligrams, and an arrow indicates the direction to turn the dial to set the desired dose for subcutaneous injection.*
FDA Label Image

Letteri-bullet (Letteri Bullet 24.jpg)

Letteri-bullet (Letteri Bullet 24.jpg)
SOGROYA injection, solution in a 3 mL glass vial with a pink cap, labeled with the strength 10 mg/mL. The vial label features the product name SOGROYA and indicates it contains somapacitan-beco. Manufactured by Novo Nordisk.*
FDA Label Image

Figure-j (Figure J 01.jpg)

Figure-j (Figure J 01.jpg)
A close-up illustration of the dose selection window on a SOGROYA (somapacitan-beco) injection pen showing a dose setting of 7.3 mg. The display window features numeric increments with a white indicator pointing to the selected dose. The pen has a blue body and a gray cap end.*
FDA Label Image

Figure-k (Figure K 01.jpg)

Figure-k (Figure K 01.jpg)
An illustration showing a dosage selector window on a SOGROYA (somapacitan-beco) injection pen, highlighting a selected dose of 2.6 mg. The window displays dose increments labeled in milligrams.*
FDA Label Image

Letteri-bullet (Letteri Bullet 25.jpg)

Letteri-bullet (Letteri Bullet 25.jpg)
SOGROYA (somapacitan-beco) injection solution packaging showing 10 mg/mL strength. The label includes product name, dosage form, route of administration as subcutaneous injection, and labeler Novo Nordisk. It appears to be a vial with a blue cap and greenish liquid inside.*
FDA Label Image

Figure-l (Figure L 01.jpg)

Figure-l (Figure L 01.jpg)
An instructional illustration showing hands adjusting a dosage dial on a SOGROYA injection device. The dial window displays a dose measurement in milligrams (mg), with arrows indicating the turning direction to set the dose. This diagram is related to subcutaneous injection dose preparation for somapacitan-beco.*
FDA Label Image

Figure-m (Figure M 01.jpg)

Figure-m (Figure M 01.jpg)
An instructional illustration showing recommended subcutaneous injection sites on the human body. The front view highlights the upper outer arms, abdomen below the waist, and front thighs; the back view highlights the upper outer arms and upper buttocks areas.*
FDA Label Image

Figure-n (Figure N 01.jpg)

Figure-n (Figure N 01.jpg)
An instructional illustration showing how to administer a subcutaneous injection using a pen device. The image depicts a hand holding the injection pen vertically against the skin, with a downward arrow indicating the direction to press the pen for delivery.*
FDA Label Image

Letteri-bullet (Letteri Bullet 26.jpg)

Letteri-bullet (Letteri Bullet 26.jpg)
SOGROYA injection solution carton labeled with Novo Nordisk as the labeler. The image shows packaging for the 10 mg/mL strength of somapacitan-beco in a subcutaneous injectable form. The carton design features branding and product strength details.*
FDA Label Image

Figure-o (Figure O 01.jpg)

Figure-o (Figure O 01.jpg)
Instructional illustration showing the proper technique for administering a subcutaneous injection using the SOGROYA injection device. The image depicts a hand holding the injection pen perpendicular to the skin, with a downward arrow indicating the direction of injection, and a dose indicator visible on the device.*
FDA Label Image

Figure-p (Figure P 01.jpg)

Figure-p (Figure P 01.jpg)
An instructional illustration showing a hand holding a SOGROYA injection pen against the skin for subcutaneous administration. The image includes a prompt to count slowly from 1 to 6 while the injection is being administered, indicating the recommended injection time.*
FDA Label Image

Letteri-bullet (Letteri Bullet 27.jpg)

Letteri-bullet (Letteri Bullet 27.jpg)
The image shows a SOGROYA injection vial, containing somapacitan-beco in a solution form for subcutaneous injection. The vial has a white cap and label with text indicating dosage information. It is indicated to be a human prescription drug, labeled by Novo Nordisk.*
FDA Label Image

Figure-q (Figure Q 01.jpg)

Figure-q (Figure Q 01.jpg)
An instructional illustration showing a subcutaneous injection needle pointing downward with an upward arrow next to it, indicating the direction for needle removal or detachment. The image is likely part of usage instructions for the SOGROYA injection device by Novo Nordisk.*
FDA Label Image

Letteri-bullet (Letteri Bullet 28.jpg)

Letteri-bullet (Letteri Bullet 28.jpg)
SOGROYA injection, solution for subcutaneous use, shown in a carton and a vial. The carton and vial label display the product name SOGROYA and indicate a strength of 10 mg/mL. The labeler is Novo Nordisk. The packaging is primarily white with blue and orange accents and includes dosage information prominently on the front.*
FDA Label Image

Figure-r (Figure R 01.jpg)

Figure-r (Figure R 01.jpg)
Instructional diagram depicting the removal of a cap from a red injection device for SOGROYA (somapacitan-beco) injection solution. The image shows a hand rotating the device cap counterclockwise to remove it, with an inset illustrating cap removal from the vial.*
FDA Label Image

Figure-s (Figure S 01.jpg)

Figure-s (Figure S 01.jpg)
Instructional diagram showing how to detach the cap from the SOGROYA injection pen. The illustration depicts a hand pulling the cap away from the pen body with an arrow indicating the direction for removal.*
FDA Label Image

Triangle-bullet (Triangle Bullet 17)

FDA Label Image

Triangle-bullet (Triangle Bullet 18)

FDA Label Image

Figure-t (Figure T 01.jpg)

Figure-t (Figure T 01.jpg)
An instructional illustration showing a red injection pen with a visible window displaying the remaining medication level, indicated as approximately 3 mg left. The pen scale is marked on the side for dose measurement guidance.*
FDA Label Image

Figure-u (Figure U 01.jpg)

Figure-u (Figure U 01.jpg)
An illustration showing a hand adjusting a dose indicator on a subcutaneous injection pen device. The dose window displays numeric values with an example reading of 4.8 mg remaining on the device.*
FDA Label Image

Triangle-bullet (Triangle Bullet 19)

FDA Label Image

Phone-qrcode (Phone Qrcode.jpg)

FDA Label Image

Figure-a-penmate (Figure A Penmate.jpg)

Figure-a-penmate (Figure A Penmate.jpg)
An illustration labeled 'PenMate' showing three views of a blue device component for a drug delivery pen. The parts labeled include the PenMate cap with a charm slot, the PenMate window, and the insertion button, demonstrating the design and functional elements of the PenMate accessory.*
FDA Label Image

Figure-b-pen (Figure B Pen.jpg)

Figure-b-pen (Figure B Pen.jpg)
Illustration of the SOGROYA (somapacitan-beco) injection pen showing labeled components including pen cap, front stopper, needle thread, growth hormone scale, pen window, display window, dose pointer, dose selector, and dose button. The diagram visually explains the parts of the subcutaneous injection delivery device.*
FDA Label Image

Figure-c-needleparts (Figure C Needleparts.jpg)

Figure-c-needleparts (Figure C Needleparts.jpg)
Illustration showing components related to SOGROYA (somapacitan-beco) injection administration, including outer needle cap, inner needle cap, needle (up to 8 mm length), paper tab, alcohol swabs, and a sharps disposal container. This diagram represents the injection accessories and disposal tools associated with the subcutaneous injection dosage form.*
FDA Label Image

Figure-d-pencase (Figure D Pencase.jpg)

Figure-d-pencase (Figure D Pencase.jpg)
Illustration of a pen case for SOGROYA (somapacitan-beco) injection. The case is shown open, designed to hold the injection pen, but the pen and needles are not included in the case as noted in the image.*
FDA Label Image

Figure-e (Figure E.jpg)

Figure-e (Figure E.jpg)
An instructional illustration showing how to remove a PenMate cap from a device, with a hand gripping the cap and an arrow indicating the direction to pull it off.*
FDA Label Image

Figure-f (Figure F.jpg)

Figure-f (Figure F.jpg)
Illustration showing the removal of a pen cap from an injection device, identified as figure F, with labels pointing to the pen cap and demonstrating the direction to pull the cap off.*
FDA Label Image

Figure-g (Figure G.jpg)

Figure-g (Figure G.jpg)
Illustration showing a close-up of the pen window area on a SOGROYA injection device, highlighting how to view or use this part of the subcutaneous injection pen.*
FDA Label Image

Figure-h (Figure H.jpg)

Figure-h (Figure H.jpg)
An instructional diagram labeled 'Figure H' showing a hand holding a cloth or wipe, cleaning the front stopper of a device or vial. The front stopper is pointed out with a label. The image is likely part of medication preparation or administration steps.*
FDA Label Image

Figure-i (Figure I.jpg)

Figure-i (Figure I.jpg)
An instructional illustration labeled Figure I showing a hand inserting a pen device's part by pressing the insertion button, with a display window indicated on the device. This appears to be a step in preparing a subcutaneous injection device.*
FDA Label Image

Figure-j (Figure J.jpg)

Figure-j (Figure J.jpg)
An instructional illustration labeled Figure J showing hands peeling a paper tab from a component, likely part of a medication delivery device. The image highlights the action of removing the paper tab by pulling it away with the fingers.*
FDA Label Image

Figure-k (Figure K.jpg)

Figure-k (Figure K.jpg)
An instructional illustration showing the hands holding a SOGROYA (somapacitan-beco) injection pen. The image demonstrates the step of twisting or removing a part at the end of the pen as indicated by an arrow, with a close-up circle highlighting the action.*
FDA Label Image

Figure-l (Figure L.jpg)

Figure-l (Figure L.jpg)
Instructional illustration labeled 'Figure L' showing how to remove the outer needle cap from an injection device. A hand is depicted gripping the needle cap and pulling it away from the device, indicating proper removal technique prior to subcutaneous injection.*
FDA Label Image

Figure-m (Figure M.jpg)

Figure-m (Figure M.jpg)
An instructional illustration showing a hand removing the inner needle cap from a pen injector. The image highlights the 'Inner needle cap' with a directional arrow indicating its removal, labeled as Figure M.*
FDA Label Image

Figure-n (Figure N.jpg)

Figure-n (Figure N.jpg)
An instructional illustration showing a close-up of a hand operating the dose selector on a SOGROYA injection pen. The image highlights the dose selector mechanism with a visible dosage setting display at 0.05 mg.*
FDA Label Image

Figure-o (Figure O.jpg)

Figure-o (Figure O.jpg)
An instructional diagram comparing Norditropin and Sogroya injection pen needle colors by dosage strength (5 mg, 10 mg, 15 mg). It also shows the corresponding minimum and maximum dose markings for each strength on the pen dials, illustrating dose ranges with numeric increments.*
FDA Label Image

Figure-p (Figure P.jpg)

Figure-p (Figure P.jpg)
An instructional illustration showing a close-up of a hand interacting with a device, likely an injection pen, with a window displaying dosage or usage information. The image appears to guide the user on handling or adjusting the injection device for SOGROYA somapacitan-beco injection solution.*
FDA Label Image

Figure-q (Figure Q.jpg)

Figure-q (Figure Q.jpg)
An instructional diagram showing a finger pressing the dose button on a SOGROYA injection pen to release a drop of liquid, indicating the correct dose administration step. The figure is labeled 'Figure Q'.*
FDA Label Image

Figure-r (Figure R.jpg)

Figure-r (Figure R.jpg)
Illustration showing the dose selector mechanism of a SOGROYA injection device. The image depicts a hand adjusting a dial or knob labeled with dose measurement markings, demonstrating how to select the dose before subcutaneous injection.*
FDA Label Image

Figure-s (Figure S.jpg)

Figure-s (Figure S.jpg)
An illustration showing front and back views of a human figure indicating recommended subcutaneous injection sites. Marked areas include the upper arms, abdomen, upper thighs, and upper buttocks. The figure is labeled "Figure 5."*
FDA Label Image

Figure-t (Figure T.jpg)

Figure-t (Figure T.jpg)
An instructional diagram showing a hand holding a PenMate injection device. The image highlights the locations of the insertion button and the dose button on the pen, illustrating how to operate these components.*
FDA Label Image

Figure-u (Figure U.jpg)

Figure-u (Figure U.jpg)
An instructional illustration depicting a hand holding a SOGROYA injection device. The image highlights the location of the insertion button on the pen-style injector, labeled as 'Insertion button.' This figure is intended to guide users on where to press to activate the device for subcutaneous injection.*
FDA Label Image

Figure-v (Figure V.jpg)

Figure-v (Figure V.jpg)
An instructional illustration showing a hand holding a SOGROYA injection pen, with a finger pressing the dose button. It indicates to hold the button down for 6 seconds, with a timer icon and a dose confirmation window showing '0 mg' during administration.*
FDA Label Image

Figure-w (Figure W.jpg)

Figure-w (Figure W.jpg)
An instructional illustration labeled Figure W showing a subcutaneous injection technique. The image depicts a close-up of an injection device with an arrow indicating upward movement, positioned near the skin surface to guide administration.*
FDA Label Image

Figure-x (Figure X.jpg)

Figure-x (Figure X.jpg)
An instructional diagram showing the removal of the outer needle cap from a device, illustrating how to grip and pull off the cap in a single hand motion. The illustration is labeled "Figure X" and highlights the outer needle cap with an arrow indicating the direction of removal.*
FDA Label Image

Figure-y (Figure Y.jpg)

Figure-y (Figure Y.jpg)
Illustration showing a hand holding a SOGROYA injection pen, demonstrating the step of pressing the pen against the skin for subcutaneous injection, with an arrow indicating the motion into the skin.*
FDA Label Image

Figure-z (Figure Z.jpg)

Figure-z (Figure Z.jpg)
An instructional illustration showing hands adjusting or preparing a device, likely related to administering SOGROYA (somapacitan-beco) injection. The diagram includes an arrow indicating a motion to perform with the device, emphasizing user interaction for setup or administration.*
FDA Label Image

Figure-aa (Figure Aa.jpg)

Figure-aa (Figure Aa.jpg)
Illustration showing the removal of the cap from an injection device for the subcutaneous administration of SOGROYA (somapacitan-beco) injection solution. The image demonstrates holding the device and twisting the cap to remove it prior to use.*
FDA Label Image

Figure-bb (Figure Bb.jpg)

Figure-bb (Figure Bb.jpg)
An instructional illustration labeled 'Figure BB' showing a close-up of hands adjusting or preparing a pen-type injector device, likely related to administration of SOGROYA (somapacitan-beco) subcutaneous injection.*
FDA Label Image

Figure-cc (Figure Cc.jpg)

Figure-cc (Figure Cc.jpg)
An instructional illustration showing a close-up of hands interacting with a device, likely demonstrating how to remove or adjust a component by twisting or pulling. The focus is on the proper grip and movement for operation, associated with the use of a subcutaneous injection device.*
FDA Label Image

Figure-dd (Image 01)

Figure-dd (Image 01)
An instructional illustration depicting a hand holding a subcutaneous injection pen needle near a forearm, with an arrow pointing downward toward the skin, indicating the injection direction. A small device or meter is shown nearby on the right side.*
FDA Label Image

5mg-carton (Image 88)

5mg-carton (Image 88)
Packaging label for Sogroya 5 mg prefilled pen injection, containing somapacitan-beco 3.3 mg/mL in a 1.5 mL prefilled pen for subcutaneous use. The label displays the product name, strength, dosage form, dosing frequency ('once weekly'), and includes an image of the prefilled pen. The labeler is Novo Nordisk.*
FDA Label Image

10mg-carton (Image 89)

10mg-carton (Image 89)
Packaging label for SOGROYA (somapacitan-beco) injection, 10 mg/1.5 mL (6.7 mg/mL) prefilled pen by Novo Nordisk. The label indicates subcutaneous injection use, single-patient use, and dosing increments of 0.05 mg for a total of 10 mg. The package shows a yellow and blue prefilled pen and instructions for once-weekly dosing.*
FDA Label Image

15mg-carton (Image 138)

15mg-carton (Image 138)
Sogroya 15 mg/1.5 mL (10 mg/mL) prefilled pen carton for subcutaneous injection by Novo Nordisk. The label shows a single-use pen containing 15 mg total dosage, with dosing increments of 0.1 mg. The packaging states 'once weekly' use and features the product name, strength, and labeler details. The design includes a pink pen image and branding graphics on a white and gray background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.